Lineage Cell Therapeutics, Inc.LCTXNYSE
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
0.00%
↓ 100% below average
Average (39q)
31.46%
Historical baseline
Range
High:1696.39%
Low:-610.38%
Volatility
7332.6%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 0.00% |
| Q2 2025 | -610.38% |
| Q1 2025 | -12.27% |
| Q4 2024 | -1.24% |
| Q3 2024 | 47.21% |
| Q2 2024 | 14.80% |
| Q1 2024 | -29.24% |
| Q4 2023 | 31.94% |
| Q3 2023 | -32.57% |
| Q2 2023 | -18.53% |
| Q1 2023 | 33.25% |
| Q4 2022 | -7.78% |
| Q3 2022 | 38.98% |
| Q2 2022 | -20.65% |
| Q1 2022 | 71.24% |
| Q4 2021 | -264.03% |
| Q3 2021 | -55.67% |
| Q2 2021 | -237.08% |
| Q1 2021 | -165.93% |
| Q4 2020 | 126.11% |
| Q3 2020 | -18.85% |
| Q2 2020 | 22.46% |
| Q1 2020 | -86.38% |
| Q4 2019 | 72.64% |
| Q3 2019 | 45.00% |
| Q2 2019 | -166.67% |
| Q1 2019 | 185.71% |
| Q4 2018 | -166.04% |
| Q3 2018 | 1696.39% |
| Q2 2018 | 93.36% |
| Q1 2018 | 13.79% |
| Q4 2017 | -583.33% |
| Q3 2017 | 209.09% |
| Q2 2017 | -123.91% |
| Q1 2017 | 1031.17% |
| Q4 2016 | -116.47% |
| Q3 2016 | 15.38% |
| Q2 2016 | 236.84% |
| Q1 2016 | -26.67% |
| Q4 2015 | 16.67% |